{"id":"carbutamide","rwe":[{"pmid":"41471025","year":"2025","title":"Carbutamide, an Obsolete Anti-Diabetic Drug, Has Potential as a Potent Anticolitic Agent via Azo-Conjugation with Mesalazine.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"27449705","year":"2016","title":"Study on the interactions of sulfonylurea antidiabetic drugs with normal and glycated human serum albumin by capillary electrophoresis-frontal analysis.","finding":"","journal":"Journal of separation science","studyType":"Clinical Study"},{"pmid":"16020498","year":"2005","title":"Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching.","finding":"","journal":"Clinical chemistry","studyType":"Clinical Study"},{"pmid":"11953758","year":"2002","title":"History of diabetes mellitus.","finding":"","journal":"Saudi medical journal","studyType":"Clinical Study"},{"pmid":"10691158","year":"2000","title":"Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.","finding":"","journal":"Diabetic medicine : a journal of the British Diabetic Association","studyType":"Clinical Study"}],"tags":[{"label":"carbutamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"A10BB06","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Hypoglycemic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"burcol","offLabel":[],"synonyms":["carbutamide","nadisan","nadizan","norboral","aminophenurobutane","bucarban","burcol","butisulfina","carbutamid","glybutamide","sulfaninylbutylurea","butylcarbamide"],"timeline":[],"brandName":"Burcol","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"}],"modality":"Small Molecule","drugClass":"carbutamide","explanation":"Think of it like a key fitting into a lock. Burcol is the key that unlocks the insulin release mechanism in the pancreas, allowing more glucose to be released into the bloodstream. This helps to lower blood sugar levels in people with type 2 diabetes.","oneSentence":"Burcol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells.","technicalDetail":"Burcol binds to the sulfonylurea receptor 1 (SUR1), a subunit of the ATP-sensitive potassium channel (K_ATP), which is composed of Kir6.2 and SUR1 subunits. This binding causes a conformational change in the channel, leading to its closure and depolarization of the pancreatic beta cell membrane, which ultimately triggers insulin release."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/505","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CARBUTAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARBUTAMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:12:03.508451","biosimilars":[],"competitors":[{"drugName":"glibenclamide","drugSlug":"glibenclamide","fdaApproval":"1984-05-01","relationship":"same-class"},{"drugName":"chlorpropamide","drugSlug":"chlorpropamide","fdaApproval":"1958-10-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolbutamide","drugSlug":"tolbutamide","fdaApproval":"1961-06-22","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolazamide","drugSlug":"tolazamide","fdaApproval":"1966-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glipizide","drugSlug":"glipizide","fdaApproval":"1984-05-08","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetohexamide","drugSlug":"acetohexamide","fdaApproval":"1964-12-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"carbutamide","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glibenclamide","brandName":"glibenclamide","genericName":"glibenclamide","approvalYear":"1984","relationship":"same-class"},{"drugId":"chlorpropamide","brandName":"chlorpropamide","genericName":"chlorpropamide","approvalYear":"1958","relationship":"same-class"},{"drugId":"tolbutamide","brandName":"tolbutamide","genericName":"tolbutamide","approvalYear":"1961","relationship":"same-class"},{"drugId":"tolazamide","brandName":"tolazamide","genericName":"tolazamide","approvalYear":"1966","relationship":"same-class"},{"drugId":"glipizide","brandName":"glipizide","genericName":"glipizide","approvalYear":"1984","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"acetohexamide","brandName":"acetohexamide","genericName":"acetohexamide","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1417914,"completionDate":"2015-04"},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1499650,"completionDate":"2015-05"},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":886172,"completionDate":"2015-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166471","NDDF":"005300","UNII":"E3K8P4869P","CHEBI":"CHEBI:135118","INN_ID":"615","RXNORM":"2068","UMLSCUI":"C0007080","ChEMBL_ID":"CHEMBL448570","KEGG_DRUG":"D02425","DRUGBANK_ID":"DB13406","PUBCHEM_CID":"9564","MESH_DESCRIPTOR_UI":"D002271"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":372,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BB06","allCodes":["A10BB06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 22","pmid":"41471025","title":"Carbutamide, an Obsolete Anti-Diabetic Drug, Has Potential as a Potent Anticolitic Agent via Azo-Conjugation with Mesalazine.","journal":"Pharmaceutics"},{"date":"2016 Sep","pmid":"27449705","title":"Study on the interactions of sulfonylurea antidiabetic drugs with normal and glycated human serum albumin by capillary electrophoresis-frontal analysis.","journal":"Journal of separation science"},{"date":"2005 Sep","pmid":"16020498","title":"Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching.","journal":"Clinical chemistry"},{"date":"2002 Apr","pmid":"11953758","title":"History of diabetes mellitus.","journal":"Saudi medical journal"},{"date":"2000 Jan","pmid":"10691158","title":"Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.","journal":"Diabetic medicine : a journal of the British Diabetic Association"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Burcol, also known as carbutamide, is a small molecule drug that targets the sulfonylurea receptor 1, Kir6.2. It is used to treat type 2 diabetes mellitus. The commercial status of Burcol is unknown, but it is classified as a carbutamide drug class. Key safety considerations are not well-documented. Further research is needed to understand its pharmacokinetic properties.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}